<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939689</url>
  </required_header>
  <id_info>
    <org_study_id>1095-2301</org_study_id>
    <nct_id>NCT03939689</nct_id>
  </id_info>
  <brief_title>Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone</brief_title>
  <acronym>ARROW</acronym>
  <official_title>A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Progenics Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Progenics Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, controlled, phase 2 clinical trial designed to evaluate&#xD;
      the safety and efficacy of I-131-1095 radiotherapy in combination with enzalutamide compared&#xD;
      to enzalutamide alone in participants with prostate-specific membrane antigen (PSMA)-avid&#xD;
      metastatic castration resistant prostate cancer (mCRPC) who have progressed on abiraterone.&#xD;
      Participants must be chemotherapy-naive and must be ineligible or refuse to receive&#xD;
      taxane-based chemotherapy at time of study entry. PSMA-avidity will be determined by central&#xD;
      imaging review based on assessment of 18F-DCFPyL PET/CT imaging during screening. Eligible&#xD;
      participants meeting the PSMA-avidity criteria will be randomized in a 2:1 ratio to receive&#xD;
      either I-131-1095 in combination with enzalutamide (80 participants) or enzalutamide alone&#xD;
      (40 participants). An interim analysis for efficacy will be performed after a minimum of 48&#xD;
      evaluable participants have PSA data for at least three months following the first dose of&#xD;
      randomized treatment.&#xD;
&#xD;
      All participants will be followed for efficacy, safety assessments, survival status, adverse&#xD;
      events of special interest, and new anti-cancer therapy for at least one year or to the end&#xD;
      of the study (whichever is later) following the first dose of randomized treatment. Safety&#xD;
      data will be monitored by an independent Data Monitoring Committee and the sponsor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study population includes patients with PSMA-avid mCRPC whose disease has progressed despite abiraterone therapy, and are planned for treatment with enzalutamide.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA Response Rate</measure>
    <time_frame>Up to 53 weeks</time_frame>
    <description>The proportion of participants with a PSA response according to PCWG3 criteria defined as the first occurrence of a 50 percent or more decline in PSA from baseline, confirmed by a second measurement at least 3 weeks later.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 53 weeks</time_frame>
    <description>The proportion of participants who have a partial response (PR) or complete response (CR) based on RECIST 1.1 for soft tissue or PCWG3 for bone (PCWG3-modified RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression Free Survival (rPFS)</measure>
    <time_frame>Up to 53 weeks</time_frame>
    <description>Time from randomization to the first occurrence of radiographic progression based on RECIST 1.1 for soft tissue or PCWG3-modified RECIST 1.1 for bone, respectively, or unequivocal clinical progression, or death on study from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall Survival is defined as time from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Progression</measure>
    <time_frame>Up to 53 weeks</time_frame>
    <description>Time from randomization to the date of the first PSA increase from baseline ≥ 25 percent and ≥ 2 ng/ml above nadir confirmed by a second PSA assessment defining progression ≥ 3 weeks later per PCWG3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response</measure>
    <time_frame>Up to 53 weeks</time_frame>
    <description>Time from the first date of complete response (CR) or partial response (PR) to the first occurrence of radiographic progression based on PCWG3-modified RECIST 1.1, or unequivocal clinical progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Initiation Of Next Treatment For Prostate Cancer</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Time from randomization to initiation of any new treatment for prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences Of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events As Assessed by CTCAE v5.0 (Safety Outcome Measure)</measure>
    <time_frame>After first administration of study drug to visit week 53</time_frame>
    <description>TEAEs will be summarized by SOC and PT using the frequency and percentage of participants experiencing any adverse event, experiencing each SOC and experiencing each PT within each SOC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Resulting In Discontinuation Of Study Drug (Safety Outcome Measure)</measure>
    <time_frame>After first administration of study drug to visit week 53</time_frame>
    <description>A high-level summary of TEAEs will be presented for participants who had at least one TEAE overall, seriousness, and leading to discontinuation of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination Findings (Safety Outcome Measure)</measure>
    <time_frame>At baseline and weeks 9, 17, 25, and 53</time_frame>
    <description>Percentage of patients with clinically significant abnormal changes on physical examination at weeks 9, 17, 25 and 53 will be presented by treatment group. Clinically significant abnormal physical examination findings will be captured in medical history if prior to study drug treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes In Blood Pressure (Safety Outcome Measure)</measure>
    <time_frame>Baseline to week 53</time_frame>
    <description>Percentage of patients with abnormal clinically significant changes in systolic and diastolic blood pressure will be presented by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes In Heart Rate (Safety Outcome Measure)</measure>
    <time_frame>Baseline to week 53</time_frame>
    <description>Percentage of patients with abnormal clinically significant changes in heart rate will be presented by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes In Temperature (Safety Outcome Measure)</measure>
    <time_frame>Baseline to week 53</time_frame>
    <description>Percentage of patients with abnormal clinically significant changes in body temperature will be presented by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift From Baseline In Selected Clinical Chemistry Laboratory Values At Follow-up (Safety Outcome Measure)</measure>
    <time_frame>Baseline to week 53</time_frame>
    <description>Percentage of patients with clinically significant abnormal values of potassium, sodium, magnesium, calcium (corrected) - per CTCAE5, urea and total protein - per investigator assessment will be presented by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift From Baseline In Selected Hematology Laboratory Values At Follow-up (Safety Outcome Measure)</measure>
    <time_frame>Baseline to week 53</time_frame>
    <description>Percentage of patients with clinically significant abnormal changes in hemoglobin, erythrocytes, thrombocytes, leukocytes, absolute neutrophil count, basophils, eosinophils and monocytes will be presented by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline In Overall Electrocardiogram (ECG) Assessment At Follow-up (Safety Outcome Measure)</measure>
    <time_frame>Baseline and weeks 1, 9, 17, 25, 53 (131-I-1095 + enzalutamide treatment group); Baseline and week 53 (enzalutamide treatment group)</time_frame>
    <description>Percentage of patients with abnormal clinically significant changes on electrocardiogram (ECG) per central reviewer's assessment will be presented by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Of Concomitant Medications (Safety Outcome Measure)</measure>
    <time_frame>Baseline to week 53 (concomitant medications); from week 54 up to 5 years (anti-cancer therapies only)</time_frame>
    <description>Medications will be summarized by ATC4 class and generic term using number of participants and percentages by treatment group and overall.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Castration-resistant Prostate Cancer</condition>
  <condition>Prostatic Neoplasm</condition>
  <condition>Cancer of the Prostate</condition>
  <condition>Progressive mCRPC</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>I-131-1095 in combination with enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-131-1095</intervention_name>
    <description>I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.</description>
    <arm_group_label>I-131-1095 in combination with enzalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.</description>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_label>I-131-1095 in combination with enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male ≥ 18 years of age&#xD;
&#xD;
          2. Histologically or cytologically confirmed adenocarcinoma of the prostate without&#xD;
             neuroendocrine differentiation or small cell features at initial diagnosis&#xD;
&#xD;
          3. Castration-resistant prostate cancer, with serum testosterone ≤ 50 ng/dL at Screening&#xD;
&#xD;
          4. Radiographic evidence of metastatic disease prior to Randomization or up to 21 days&#xD;
             prior to Screening&#xD;
&#xD;
          5. Disease progression on prior abiraterone therapy as defined by meeting at least one of&#xD;
             the following criteria per the investigator:&#xD;
&#xD;
               1. PSA progression as defined by a minimum of two rising PSA levels at least 1 week&#xD;
                  apart&#xD;
&#xD;
               2. Soft tissue disease progression defined by RECIST 1.1&#xD;
&#xD;
               3. Bone disease progression defined by two or more new lesions on bone scan&#xD;
&#xD;
          6. Planned to receive treatment with enzalutamide&#xD;
&#xD;
          7. Subjects who are ineligible or choose not to receive taxane-based chemotherapy based&#xD;
             on personal preference or physician opinion. Examples of conditions that could make a&#xD;
             patient ineligible or refuse to receive taxane-based chemotherapy, but would allow&#xD;
             them to still be eligible to receive I-131-1095 include the following:&#xD;
&#xD;
               1. Poor performance status&#xD;
&#xD;
               2. Prior intolerance to cytotoxic agents&#xD;
&#xD;
               3. History of another malignancy suspected for recurrence or metastases&#xD;
&#xD;
               4. Other serious medical conditions such as symptomatic peripheral neuropathy CTCAE&#xD;
                  Grade 2 or higher; or clinically significant cardiovascular disease per the&#xD;
                  Investigator or treating physician&#xD;
&#xD;
          8. Subjects receiving bisphosphonate therapy must have been on stable doses for at least&#xD;
             4 weeks prior to Randomization&#xD;
&#xD;
          9. ECOG performance status 0-2&#xD;
&#xD;
         10. If sexually active, agree to use a medically acceptable method of birth control or&#xD;
             sexual abstinence from the time of dosing through 28 days after the last dose of&#xD;
             I-131-1095. Female partners must use hormonal or barrier contraception unless&#xD;
             postmenopausal or abstinent.&#xD;
&#xD;
         11. Estimated life expectancy of at least 6 months as determined by the Investigator.&#xD;
&#xD;
         12. Able and willing to provide signed informed consent and comply with protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received any anti-tumor therapy within 4 weeks of Randomization, with the exception of&#xD;
             abiraterone, GnRH therapy and non-radioactive bone-targeted agents&#xD;
&#xD;
          2. Received prior chemotherapy for castration-resistant prostate cancer&#xD;
&#xD;
          3. Superscan as evidenced on baseline bone scan&#xD;
&#xD;
          4. Treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 within&#xD;
             6 months prior to Randomization&#xD;
&#xD;
          5. Prior hemi-body irradiation&#xD;
&#xD;
          6. Prior PSMA-targeted radioligand therapy&#xD;
&#xD;
          7. Major surgery within 4 weeks of Randomization&#xD;
&#xD;
          8. Impaired organ function as evidenced by the following laboratory values at Screening:&#xD;
&#xD;
               1. Absolute neutrophil count &lt; 1500 μL&#xD;
&#xD;
               2. Platelet count &lt; 100,000/μL&#xD;
&#xD;
               3. Hemoglobin &lt; 9.5 g/dL&#xD;
&#xD;
               4. Albumin &lt; 3.0 g/dL (30 g/L)&#xD;
&#xD;
               5. Total bilirubin &gt; 2 x ULN unless in instances of known or suspected Gilbert's&#xD;
                  disease&#xD;
&#xD;
               6. AST or ALT &gt; 2.5 x ULN&#xD;
&#xD;
               7. Calculated creatinine clearance (CrCL) &lt; 30 mL/min (Cockroft-Gault equation), or&#xD;
                  currently on renal dialysis.&#xD;
&#xD;
          9. QT interval corrected for heart rate (QTc) &gt; 470 msec&#xD;
&#xD;
         10. Previous use of enzalutamide for more than 7 days prior to consent&#xD;
&#xD;
         11. Planned initiation of alternative therapy for prostate cancer, investigational&#xD;
             therapy, or participation in clinical trials during the study&#xD;
&#xD;
         12. History or risk of seizure (i.e., clinically significant neurological disorder) or any&#xD;
             other condition that contraindicates treatment with enzalutamide&#xD;
&#xD;
         13. Gastrointestinal disorder affecting absorption of oral medications&#xD;
&#xD;
         14. Known or suspected brain metastasis or active leptomeningeal disease&#xD;
&#xD;
         15. Active malignancy other than prostate cancer, with the exception of curatively treated&#xD;
             non-melanoma skin cancer, carcinoma in situ, or non-muscle invasive bladder/urothelial&#xD;
             cancer&#xD;
&#xD;
         16. Subjects with any medical condition or other circumstances that, in the opinion of the&#xD;
             investigator, compromise obtaining reliable data, achieving study objectives, or&#xD;
             completing the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only male subjects will be enrolled in this study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Istvan Molnar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Progenics Clinical Trials Contact</last_name>
    <phone>646-975-2521</phone>
    <email>clinical-trials-contact@Progenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Simpson</last_name>
      <phone>626-218-5087</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Alas</last_name>
      <email>Alexander.Alas@va.gov</email>
    </contact>
    <contact_backup>
      <phone>310-268-3547</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7370</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soosan Roodbari</last_name>
      <email>SRoodbari@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoag Family Cancer Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheree Phillips</last_name>
      <email>Sheree.phillips@hoag.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Healthcare System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nithya Vijayakumar</last_name>
      <phone>650-353-8561</phone>
      <email>NVijayakumar@pavir.org</email>
    </contact>
    <investigator>
      <last_name>Minal Vasanawala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piscilla Wong</last_name>
      <email>pw504@georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyebin Roh</last_name>
      <email>hroh1@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Howsare</last_name>
      <phone>319-384-6469</phone>
      <email>veronica-howsare@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane Medical School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Cotogno</last_name>
      <phone>504-988-6542</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Besche</last_name>
      <phone>410-328-8610</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Yun</last_name>
      <email>James.yun@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Carusone</last_name>
      <email>carusonn@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Fillare</last_name>
      <phone>215-746-8192</phone>
      <email>Matthew.Fillare@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Pryma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LifeSpan Cancer Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>09206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Grand</last_name>
      <email>dgrand@lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Wheeler</last_name>
      <phone>843-792-2306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujay Rao</last_name>
      <email>srao@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jannefer Sengmany</last_name>
      <phone>206-287-6278</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Goyal</last_name>
      <email>sgoyal@seattlecca.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Proulx</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70316</phone_ext>
      <email>caproulx@toh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah DeBrabandere</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>56399</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edlira Zela</last_name>
      <email>Edlira.Zela@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Del' Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Brisson</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>35817</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Bitton</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>26159</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise St-Onge</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>20414</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsie Morneau</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>56399</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Afshar-Oromieh A, Haberkorn U, Zechmann C, Armor T, Mier W, Spohn F, Debus N, Holland-Letz T, Babich J, Kratochwil C. Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):950-959. doi: 10.1007/s00259-017-3665-9. Epub 2017 Mar 9.</citation>
    <PMID>28280855</PMID>
  </reference>
  <reference>
    <citation>Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92. doi: 10.1007/s00259-014-2713-y. Epub 2014 Feb 28.</citation>
    <PMID>24577951</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone metastases</keyword>
  <keyword>18F-DCFPyL</keyword>
  <keyword>PSMA PET</keyword>
  <keyword>PSMA-avidity</keyword>
  <keyword>biomarker</keyword>
  <keyword>radioligand therapy</keyword>
  <keyword>adjunct radiation therapy</keyword>
  <keyword>dosimetry</keyword>
  <keyword>SPECT/CT</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

